-
Lovastatin Workflows for Mechanistic Cell Research
2026-09-25
Use Lovastatin to connect HMG-CoA reductase inhibition with measurable changes in cell growth, apoptosis, and macrophage efferocytosis. This guide pairs practical dose-finding and controls with evidence limits, so metabolic effects are not mistaken for a single downstream phenotype.
-
Macrophage-Targeted STING Editing for Lung Fibrosis
2026-09-25
Wang et al. developed an inhalable phosphatidylserine-bearing lipid nanoparticle that delivers CRISPR-Cas9 components to pulmonary macrophages, enabling targeted Sting1 editing in a mouse fibrosis model. The study links improved cell-selective delivery to reduced STING signaling and fibrotic pathology, while leaving important questions about durability, safety, and translation to human IPF unresolved.
-
OMV Display of mRNA Antigens for Tumor Vaccines
2026-09-24
The study engineered bacterial outer membrane vesicles to bind box C/D-tagged mRNA antigens and promote their delivery to dendritic cells, combining rapid antigen loading with bacterial immune stimulation. In mouse tumor models, the platform inhibited tumor growth, produced complete regression in a subset of colon cancer cases, and supported immune protection on later tumor challenge—findings that motivate further study while leaving clinical translation questions open.
-
β-Catenin–BCL9 Inhibition Reverses Checkpoint Resistance
2026-09-24
Feng and colleagues used hydrocarbon-stapled peptides to disrupt β-catenin binding to BCL9/B9L, inhibiting Wnt signaling and suppressing tumor growth in preclinical models. The study’s key translational finding is that this intervention also remodeled the tumor immune environment—reducing regulatory T cells and increasing dendritic cells—so tumors became more responsive to PD-1 blockade.
-
EZ Cap™ Cas9 mRNA for Neurodegeneration Editing
2026-09-23
EZ Cap™ Cas9 mRNA (5-moUTP) is a capped, modified Cas9 mRNA designed for guide-RNA-directed genome editing. This article connects the product’s documented features with a zebrafish Fyn–Stat3 neurodegeneration study while clarifying that the study did not test this product.
-
Naringin, VEGFC, and Fibrosis in NASH
2026-09-23
This study identifies a hepatocyte VEGFC–macrophage regulatory axis that links metabolic liver injury to inflammatory macrophage behavior and hepatic fibrosis. Using pharmacological inhibition, hepatocyte-specific Vegfc deletion, clinical data, and cell-based assays, the authors show that naringin protects against NASH-associated fibrosis partly by suppressing VEGFC signaling through VEGFR-3 and the CCL2/CCR2 pathway.
-
GS-441524: Matrix-Aware Assay Design
2026-09-22
GS-441524 research benefits from separating parent compound, converted metabolite, and phosphorylated species across biological matrices. This article translates recent LC–MS/MS evidence into a practical framework for antiviral assay design, sample handling, and GS-441524 pharmacokinetics.
-
MLN2238: Proteasome β5 Inhibitor Workflow
2026-09-22
MLN2238 enables controlled, reversible chymotrypsin-like proteasome inhibition for mechanistic oncology, stress-response, and drug-resistance studies. This workflow connects target engagement with apoptosis and ROS/JNK/CREB readouts while addressing solubility, selectivity, and timing pitfalls.
-
11β-HSD1 Inhibition Rewires Antifibrotic Immunity
2026-09-21
A 2025 mouse study shows that inhibiting 11β-HSD1 can reduce thioacetamide-induced liver fibrosis through two linked mechanisms: suppression of Notch signaling and enhancement of natural killer cell activity. The work connects altered intracellular cortisol metabolism with hepatic stellate cell control and provides a mechanistic framework for future liver fibrosis research.
-
Lovastatin Workflow for Mechanistic Cell Studies
2026-09-21
Build a reproducible Lovastatin workflow around mevalonate-pathway perturbation, with practical guidance for proliferation, apoptosis, macrophage efferocytosis, and cancer research. A plant meristem study adds a useful time-resolved framework for separating direct pathway effects from downstream phenotypes without overextending the evidence.
-
CCL7+ Macrophages and Colorectal Cancer Immunotherapy
2026-09-20
This study identifies macrophage-derived CCL7 as a mediator of colorectal cancer resistance to PD-L1 blockade. Its experiments connect CCL7 with PI3K-AKT-PEX3 metabolic programming in tumor-associated macrophages and with suppression of the AKT2-STAT1-CXCL10 pathway that supports activated CD8+ T-cell infiltration.
-
Ibrexafungerp Against Echinocandin-Resistant Candida
2026-09-19
This study evaluated ibrexafungerp against 192 clinically collected Candida isolates with phenotypic or genotypic echinocandin resistance, resolving susceptibility by species and FKS hotspot mutation. Its findings show retained activity in many isolates, but also reveal mutation-position and species-dependent differences that matter for resistance interpretation and translational study design.
-
Exosomal miR-17-5p in Sepsis Lung Injury
2026-09-18
The reference study identifies a plasma extracellular-vesicle miR-17-5p–Bcl11b axis that modulates macrophage polarization and sepsis-associated lung injury. Its combined clinical-sample, cell, animal, transcriptomic, and reporter-assay design provides a useful framework for evaluating extracellular miRNAs as mechanistic biomarkers, while also highlighting an apparent directional inconsistency in the reported conclusion.
-
Linagliptin and the p-Tau Ser356 Question
2026-09-18
A translational framework for positioning Linagliptin (BI-1356) alongside NUAK-focused tau research, using human brain slice evidence to define what is known, what remains unproven, and how to design a disciplined repurposing study.
-
Electrical Stimulation Boosts Nanoparticle Uptake
2026-09-17
The reference study shows that alternating-current electrical stimulation increases magnetic nanoparticle endocytosis in cancer cells, primarily through macropinocytosis associated with F-actin reduction and intracellular Ca2+ elevation. The approach improved magnetic hyperthermia and MRI readouts across multiple cell and nanoparticle types, suggesting a broadly adaptable physical strategy for nanomedicine.